Evidence map›Paper›PMID 39998802›Full record

ArticleDermatology and therapy2025

Tumoral Melanosis: A Case Series of a Rare Clinical Entity.

Cesare Ariasi, Grazia Linda Artelli, Cristina Zane, Martina Perantoni, Simone Soglia, Giuseppe La Rosa, Vincenzo Maione, Marina Venturini, Claudia Zambelli, Gaetano Licata and 2 more

Erratum issuedAbstract read
In one paragraph

Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Cesare AriasiDepartment of Dermatology, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy.
Grazia Linda ArtelliDepartment of Dermatology, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy. g.artelli@unibs.it.ORCID http://orcid.org/0009-0003-7227-3139
Cristina ZaneDepartment of Dermatology, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy.
Martina PerantoniDepartment of Dermatology, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy.
Simone SogliaDepartment of Dermatology, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy.
Giuseppe La RosaDepartment of Dermatology, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy.
Vincenzo MaioneDepartment of Dermatology, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy.
Marina VenturiniDepartment of Dermatology, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy.
Claudia ZambelliDepartment of Pathology, University of Brescia, Brescia, Italy.
Gaetano LicataDepartment of Dermatology, Sant'Antonio Abate Hospital, Trapani, Italy.
Mariateresa RossiDepartment of Dermatology, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy.
Mariachiara ArisiDepartment of Dermatology, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumoral melanosis (TM) is a rare entity thought to result from the complete regression of melanoma. Clinically, TM resembles malignant melanocytic lesions, presenting as hyperpigmented flat or papulonodular lesions. Histologically, TM lacks melanocytes, instead showing inflammation, fibrosis, and melanophages. Diagnosing melanoma without melanocytes is challenging, and TM may also represent other regressed benign or malignant pigmented lesions. This study retrospectively analyzed 12 TM cases focusing on the clinical course, management, and potential for malignancy. Among the cases, 50% were associated with advanced or metastatic melanoma, supporting TM's potential as a regressed melanoma. Conversely, in 50% of cases, TM occurred without primary or metastatic melanoma, suggesting possible regression of a benign or malignant epithelial lesion such as pigmented basal cell carcinoma (BCC) or seborrheic keratosis (SK) or confinement of melanoma by the immune system. Management included surgical excision and follow-up similar to that of melanoma. Sentinel lymph node biopsy (SLNB) was selectively performed based on clinical suspicion and multidisciplinary team discussions. In conclusion, TM should be considered potentially regressed melanoma, especially in patients with high disease burden, and the possibility of derivation from high-grade melanomas must always be considered. Given the inability to distinguish TM from completely regressed melanoma, clinicians must remain vigilant and suspect this origin during staging and follow-up. Comprehensive management and close monitoring are crucial to address TM's clinical implications.

Indexed as

Completed regressed melanomaMelanomaRegressionTumoral melanosis

Identifiers

PMID39998802
PMCPMC12033144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.